Has William Tap, MD received payments from drug or device companies?

Yes. Drug and device makers reported $259,893 in general payments to William Tap, MD across 144 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean William Tap, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about William Tap, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

William Tap, MD

Hematology & Oncology · New York, NYNPI 1538193446

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $192,131 of the $259,893 with a category attached, or 73.9%. 19 manufacturers reported payments, led by Daiichi Sankyo Inc. at 41.2% of the total. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$259,893in general payments, 2019–2025

Across 144 payments — averaging $1804.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$107K
Deciphera Pharmaceuticals Inc.$35K
Boehringer Ingelheim$18K
EMD Serono, Inc.$17K
Servier Bioinnovation$14K
Boehringer Ingelheim International GmbH$13K
plus $56K from 13 others

$4,761,011in research payments, 2019–2025

Across 329 payments — averaging $14,471 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

GSK$2.4M
Deciphera Pharmaceuticals Inc.$916K
Eli Lilly$340K
Servier Bioinnovation$323K
Agios Pharmaceuticals, Inc.$270K
Blueprint Medicines Corporation$259K
plus $208K from 2 others

What the payments were for

Consulting fees$192,13174%
Speaking & faculty fees$52,84520%
Travel & lodging$11,2594%
Food & beverage$3,4261%
Education$200%
Gifts$2120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	50	$107,117
Deciphera Pharmaceuticals Inc.	33	$35,005
Boehringer Ingelheim	9	$17,812
EMD Serono, Inc.	14	$16,954
Servier Bioinnovation	4	$13,545
Boehringer Ingelheim International GmbH	5	$13,163
Ipsen Bioscience Inc.	3	$11,550
Servier Pharmaceuticals LLC	3	$8,160
Aadi Bioscience, Inc.	2	$7,965
EMD Serono Research & Development Institute, Inc.	2	$6,373
Recordati_rare_diseases_inc.	6	$6,344
Amgen	2	$5,192
Bayer	2	$3,695
GSK	1	$1,900
Eli Lilly	4	$1,573
Kowa Research Institute, Inc.	1	$1,500
Agios Pharmaceuticals, Inc.	1	$1,500
Merck Kgaa	1	$525
Merck	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Turalio$91,127
QINLOCK$24,075
TIBSOVO$11,560
VIMSELTINIB$6,243
Vitrakvi$2,100
FYARRO$1,770
Stivarga$1,595
ROMVIMZA$1,488

How this compares

$259,893 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York →

Medicare billing

Part B allowed, 2024

$42,450

Medicare patients

108

Services billed

312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CabometyxCabozantinib S-Malate	13	$309,657
VerzenioAbemaciclib	14	$218,274
GleevecImatinib Mesylate	20	$214,066
Imatinib Mesylate	73	$165,465
VotrientPazopanib Hcl	11	$84,560
Dexamethasone	14	$240
Amlodipine Besylate	13	$190

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in New York

Michael SchusterNew York$1.6M
Charles SawyersNew York$1.6M
Manuel Hidalgo-MedinaNew York$1.4M
Ross LevineNew York$968K
Joshua SabariNew York$761K
Gail RobozNew York$738K
Jeffrey LaurenceNew York$640K
John AllanNew York$580K
Ilan ShapiraNew York$475K
John MascarenhasNew York$456K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →